03:58 AM EDT, 04/08/2025 (MT Newswires) -- SOPHiA GENETICS ( SOPH ) partnered with Precision for Medicine to enhance biomarker discovery and precision medicine services, Precision for Medicine said Tuesday.

The company said it will integrate SOPHiA's DDM Platform for biomarker discovery, clinical trial assays, and advanced algorithms to expand its clinical trial capabilities.

The partnership will enable biopharma companies to accelerate clinical trial design, patient stratification, and data analysis through AI-driven algorithms that analyze complex multimodal data, including genomic, radiomic, and clinical data, the company said.

Additionally, the company said the MSK-ACCESS liquid biopsy test powered by SOPHiA DDM, supported by AstraZeneca ( AZN ) , will be available as a service for biopharma clients.